Abstract: An information processing device, a program, and an information processing method are provided, capable of instructing an imaging device to start and end a predetermined operation through an operation via a GUI. The information processing device includes: a display control unit configured to control display of a slider on a display unit, the slider being configured such that a display object is movable between predetermined positions; and a process control unit configured to instruct an imaging unit to control photography in a predetermined mode when the process control unit receives an operation of moving the display object.

Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

Abstract: The invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof. In addition, the invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, by adding a surfactant and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof.

Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.

Abstract: The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: wherein R1 is aralkyl, etc.; R2 is H, etc.; —W4?W5—W6?W7— is a group of the formula: —CR4?CR5—CR6?CR7— (in which R4, R5, R6 and R7 are independently a group of the formula: -E-A (E is a single bond, etc., A is H or nitro, etc.)), etc.; R8 is a group of the formula: —OR11 (R11 is H, etc.), etc.; R9 is trifluoromethyl, etc.; R10 is a group of the formula: —[C(R13)(R14)]n—R15 (R13 and R14 are independently H, etc., n is an integer of 0 to 10, R15 is a group of the formula: N(R18)R19 (R18 and R19 form a nitrogen-containing heteromonocycle together with a nitrogen atom to which they are bonded), etc.).

Abstract: Provided is a heat treatment method wherein generation of slip dislocation in silicon wafer RTP is suppressed, in order to solve a problem of not sufficiently suppressing generation of slip dislocation of silicon wafers in conventional RTP. A step is provided for suspending temperature rising for 10 seconds or longer at a temperature in a range of over 700° C. to below 950° C., so as to prevent generation of slip dislocation during rapid heating, at least at a silicon wafer portion that contacts with a supporting section of a rapid heating apparatus or at a portion on the outermost circumference section of the silicon wafer.

Abstract: The present invention provides an ophthalmic percutaneous absorption type preparation containing an ophthalmic drug and a vasoconstrictor, which can increase the amount of the ophthalmic drug transferred through the eyelid to a topical area in the eye, particularly the anterior segment of the eye such as conjunctiva, lacrimal fluid, aqueous humor, cornea and the like by administration to the skin surface of an eyelid.

Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.

Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises epinastine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising epinastine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby causing transfer of a therapeutically effective amount of epinastine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.

Abstract: A steam condenser which condenses steam exhausted from a steam turbine. Heat transfer tubes are arrayed below the steam turbine inside the container. Cooling medium flows inside the heat transfer tubes. The heat transfer tubes extend horizontally, and include at least two upper heat transfer tube groups and at least two lower heat transfer tube groups arranged with a gap between each other. Each heat transfer tube group is constituted by arraying heat transfer tubes like a grid. At a lower part between the lower heat transfer tube groups, a baffle plate which obstructs flow of steam extends horizontally. Between the upper and lower heat transfer tube groups, inter-tube-group inundation prevention plates extend horizontally. In each heat transfer tube group, an enclosure part extends to guide gas from the enclosure part to outside of the container through a gas extraction duct.

Abstract: A steam condenser which condenses steam exhausted from a steam turbine. Heat transfer tubes are arrayed below the steam turbine inside the container. Cooling medium flows inside the heat transfer tubes. The heat transfer tubes extend horizontally, and include at least two upper heat transfer tube groups and at least two lower heat transfer tube groups arranged with a gap between each other. Each heat transfer tube group is constituted by arraying heat transfer tubes like a grid. At a lower part between the lower heat transfer tube groups, a baffle plate which obstructs flow of steam extends horizontally. Between the upper and lower heat transfer tube groups, inter-tube-group inundation prevention plates extend horizontally. In each heat transfer tube group, an enclosure part extends to guide gas from the enclosure part to outside of the container through a gas extraction duct.

Abstract: A pharmaceutical composition containing: (i) a complex comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), analogues thereof and variants thereof, which is bound to at least one substance selected from the group consisting of polysaccharides and derivatives thereof; and (ii) a substance that suppresses the production of prostaglandins and/or a substance that competes with a biological action of prostaglandins, shows prolonged retention of said OCIF, analogue thereof or variant thereof in the bloodstream after administration and enhanced pharmacological activity, making it useful in the treatment and prophylaxis of bone metabolic diseases. The method of treatment and/or prophylaxis of such diseases by administration of effective amounts of (i) said complex and of (ii) said substance, is also provided.

Abstract: A pharmaceutical composition which contains (i) a complex of (a) one or more OCIF substances selected from the group consisting of an osteoclastogenesis inhibitory factor, an analog thereof and a variant thereof, and (b) a polysaccharide substance comprising a polysaccharide or a derivative thereof and (ii) a substance suppressing production of a prostaglandin and/or a substance competing an action of a prostaglandin. The invention also provides a method for treatment or prevention of a bone metabolic disease by administering to a patient in need thereof, an effective amount of (i) a complex of (a) one or more OCIF substances selected from the group consisting of an osteoclastogenesis inhibitory factor, an analog thereof and a variant thereof, and (b) a polysaccharide substance comprising a polysaccharide or a derivative thereof, and of (ii) a substance suppressing production of prostaglandin and/or a substance competing an action of prostaglandin.